N
Nura Bio
Clinical-stage SARM1 inhibitors for axon-protective neurotherapeutics
About Nura Bio
Nura Bio is a South San Francisco clinical-stage biopharmaceutical company developing oral neuroprotective small molecules that inhibit SARM1, a NAD hydrolase that drives axon degeneration across central, peripheral and ocular nervous-system diseases. Led by CEO Shilpa Sambashivan, its pipeline includes NB-4746, a brain-penetrant reversible orthosteric SARM1 inhibitor in a Phase 1b/2a ALS study after a healthy-volunteer Phase 1 that showed favorable safety and target CSF exposure, and NB-9402, a next-generation covalent allosteric SARM1 inhibitor that has entered first-in-human dosing. In June 2026 Nura Bio completed a $73.8 million Series B financing led by The Column Group, with Euclidean Capital, Samsara BioCapital and Sanofi Ventures, to fund clinical proof-of-biology studies for its SARM1 inhibitor portfolio. Sources: Nura Bio / GlobeNewswire 22 Jun 2026.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- San Francisco, United States
- Employees
- 33
- Open positions
- 3
- Dealroom signal
- 50.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Neurology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jun 2026 | $74M | $295M | Undisclosed | ↗ |
| SERIES AOther financing | Sep 2024 | $68M | $272M | Sanofi Ventures · Euclidean Capital · Samsara BioCapital · The Column Group | ↗ |
Growth signals
Latest recorded traffic for Nura Bio is 4K monthly website visits, up 66.7% over the last three months. Nura Bio's team grew 10% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
The Column Group- ECEuclidean Capital
Samsara BioCapital
Sanofi Ventures
Other known investors2 additional known investors
Oregon Health & Science University- TSThe University of Texas Southwestern Medical School
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nura Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nura Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.